OR WAIT null SECS
February 14, 2019
The multi-year agreement will give Novartis access to AbCellera’s expertise and state-of-the-art antibody discovery technology for up to ten clinically-relevant disease targets.
February 02, 2019
New platform technologies, advanced modeling tools, and addressing patient needs are important developments.
Biosimilars, pricing strategies, and technology will influence growth in spending on drugs.
The market for biosimilars in Europe remains consistently robust, with 16 new biosimilars approved in 2018.
Novel analytical methods may help biologics manufacturers respond to stricter regulations on particulate matter.
February 01, 2019
Janssen and MeiraGTx will collaborate on the development and commercialization of gene therapies for treating inherited retinal diseases.
Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex therapeutic classes.
January 17, 2019
Lonza and Takeda have furthered their multiproduct partnership through collaborative efforts on a new cancer treatment-Alunbrig (brigatinib).
January 15, 2019
The agreement gives Sanofi access to Biomunex’s proprietary bi- and multi-specific-antibody-generating platform.
January 07, 2019
The new reagents are designed to support clinical-phase and commercialization stages of cell and gene therapy production and to enhance DNA transfection.